
Core Insights - Aclarion, Inc. has expanded the availability of its Nociscan product to Santa Monica, enhancing access to its MRI and diagnostic imaging services for chronic low back pain [1][2] - Nociscan is the first evidence-supported SaaS platform that helps physicians differentiate between painful and nonpainful discs in the lumbar spine, utilizing biomarkers and AI algorithms [4][6] - Chronic low back pain affects approximately 266 million people globally, highlighting the significant market potential for Aclarion's solutions [3] Company Overview - Aclarion, Inc. leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments, specifically targeting the chronic low back pain market with its Nociscan platform [6] - The company’s Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][6] Market Context - Los Angeles, with a population exceeding 3.8 million, represents a strategically important market for Aclarion, alongside New York City [3] - The expansion of Nociscan services to Santa Monica is part of MICSC's commitment to adopting innovative solutions that enhance patient care and physician support [2]